521 related articles for article (PubMed ID: 29487224)
1. Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.
Tannir NM; Pal SK; Atkins MB
Oncologist; 2018 May; 23(5):540-555. PubMed ID: 29487224
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib for the treatment of renal cell carcinoma.
Escudier B; Lougheed JC; Albiges L
Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047
[TBL] [Abstract][Full Text] [Related]
3. [Not Available].
Borchiellini D
Bull Cancer; 2018 Dec; 105 Suppl 3():S242-S254. PubMed ID: 30595153
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib for the treatment of kidney cancer.
Študentová H; Vitásková D; Melichar B
Expert Rev Anticancer Ther; 2018 Jun; 18(6):511-518. PubMed ID: 29737893
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.
Osanto S; van der Hulle T
Ther Adv Urol; 2018 Mar; 10(3):109-123. PubMed ID: 29662541
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis.
Karner C; Kew K; Wakefield V; Masento N; Edwards SJ
BMJ Open; 2019 Mar; 9(3):e024691. PubMed ID: 30826762
[TBL] [Abstract][Full Text] [Related]
7. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
Jain RK; Gandhi S; George S
Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.
Tannir NM; Schwab G; Grünwald V
Curr Oncol Rep; 2017 Feb; 19(2):14. PubMed ID: 28247252
[TBL] [Abstract][Full Text] [Related]
9. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
Amzal B; Fu S; Meng J; Lister J; Karcher H
PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
[TBL] [Abstract][Full Text] [Related]
10. Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma.
Zahoor H; Rini BI
Expert Opin Emerg Drugs; 2016 Dec; 21(4):431-440. PubMed ID: 27690664
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
Markham A
Target Oncol; 2022 Mar; 17(2):193-201. PubMed ID: 35175500
[TBL] [Abstract][Full Text] [Related]
12. Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.
Oudard S; Joly F; Geoffrois L; Laguerre B; Houede N; Barthelemy P; Gross-Goupil M; Vano Y; Lucidarme O; Bidault F; Kelkouli N; Slimane K; Escudier B
Clin Genitourin Cancer; 2016 Dec; 14(6):e595-e607. PubMed ID: 27283478
[TBL] [Abstract][Full Text] [Related]
13. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.
O'Reilly A; Larkin J
Expert Rev Clin Pharmacol; 2017 Mar; 10(3):251-262. PubMed ID: 28224821
[TBL] [Abstract][Full Text] [Related]
15. Treatment sequences for advanced renal cell carcinoma: A health economic assessment.
Deniz B; Ambavane A; Yang S; Altincatal A; Doan J; Rao S; Michaelson MD
PLoS One; 2019; 14(8):e0215761. PubMed ID: 31465470
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib: A Review in Advanced Renal Cell Carcinoma.
Al-Salama ZT; Keating GM
Drugs; 2016 Dec; 76(18):1771-1778. PubMed ID: 27909994
[TBL] [Abstract][Full Text] [Related]
17. Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.
Grande E; Glen H; Aller J; Argenziano G; Lamas MJ; Ruszniewski P; Zamorano JL; Edmonds K; Sarker S; Staehler M; Larkin J
Expert Opin Drug Saf; 2017 Dec; 16(12):1413-1426. PubMed ID: 28920492
[TBL] [Abstract][Full Text] [Related]
18. Advances in treatment of metastatic renal cell carcinoma.
Gong J; Gerendash B; Dizman N; Khan A; Pal SK
Curr Opin Urol; 2016 Sep; 26(5):439-46. PubMed ID: 27467136
[TBL] [Abstract][Full Text] [Related]
19. Current management of metastatic renal cell carcinoma: evolving new therapies.
Kumar R; Kapoor A
Curr Opin Support Palliat Care; 2017 Sep; 11(3):231-237. PubMed ID: 28590313
[TBL] [Abstract][Full Text] [Related]
20. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]